They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier. Depending on the amount of clinical trial data required by regulators, it may not be possible to realize a current plan to launch an Omicron-targeting vaccine by the end of March, BioNTech said. Still, the U.S. Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has provided 90% protection against hospitalization due to COVID-19. “The goal of this vaccine is to protect against serious illness,” said Dr. Paul Offit, an infectious disease expert at the University of Pennsylvania. “To date, these vaccines do that, including protection against Omicron.”Subscribe to our daily newsletter By providing an email address.

Source: Philippine Daily Inquirer January 26, 2022 01:10 UTC